Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Acadia Pharmaceuticals Is Soaring

By Brian Feroldi - Nov 28, 2018 at 11:01AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Shares rebound after the company announces the pricing details of its common stock offering.

What happened

In response to the release of the pricing details of its just-announced secondary common stock offering, shares of Acadia Pharmaceuticals (ACAD -0.56%), a commercial-stage biopharma, jumped as much as 16% in early-morning trading on Wednesday. Shares were up about 10% as of 10:34 a.m. EST.

So what

Acadia stated that it is selling 16.2 million shares to the public at a price of $17 per share. The gross proceeds from the deal will be about $275 million before subtracting fees. The underwriters of the deal will also be granted an option to purchase an additional 2.4 million shares.

Man with money in his hands.

Image source: Getty Images.

In total, the company could raise about $316 million. That's $86 million more than was previously announced.

What's more, the $17 offering price is the exact same figure as Tuesday's closing price. That suggests that the company didn't have to offer a big discount in order to attract enough demand.

Traders appear to be cheering based on the super-sized deal terms.

Now what

If you add this cash infusion to Acadia's existing cash hoard, its bank balance at the end of the year should be around $450 million or so. That should be plenty of capital to fund the company's continued commercial expansion and ongoing clinical trials for at least two more years if current spending rates persist.

With plenty of cash in the bank, investors can now turn their attention to Nuplazid's ramping sales growth and the drug's label expansion potential. There's still a lot of work to do on both fronts, but bulls have plenty of reasons to remain optimistic.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Acadia Pharmaceuticals Stock Quote
Acadia Pharmaceuticals
ACAD
$15.19 (-0.56%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
323%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.